Publication|Articles|November 17, 2026

Pharmacy Times

  • November 2026
  • Volume 92
  • Issue 11

Recap: Phentolamine Ophthalmic Solution Approved for Presbyopia in Adults

A once-nightly drop already used to reverse pupil dilation gains a near-vision indication.

The FDA has approved phentolamine ophthalmic solution 0.75% (Ryzumvi; Viatris), an α-adrenergic antagonist eye drop, for the treatment of presbyopia in adults. The preservative-free drop is instilled once nightly. It offers a new pharmacologic option for the nearly 128 million individuals in the US with presbyopia, or about 90% of adults older than 45 years. Phentolamine ophthalmic solution was first approved for the reversal of pharmacologically induced mydriasis. Viatris says it is the only commercially available FDA-approved product for that use.1,2

Related to this article